Associated Papers
Real-World Evidence of the Prevalence of Driver Mutations in Anorectal Melanoma.
Jutten E et al.
Molecular Diagnosis & Therapy, 2025
Poor Applicability of Currently Available Prognostic Scoring Systems for Prediction of Outcome in KIT D816V-Negative Advanced Systemic Mastocytosis.
Naumann N et al.
Cancers, 2024
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2023
Rapid response to avapritinib of acute myeloid leukemia with t(8;21) and KIT mutation relapse post allo-HSCT.
Xue S et al.
Leukemia & Lymphoma, 2022
Systematic review and meta-analysis of genomic alterations in acral melanoma.
Broit N et al.
Pigment Cell & Melanoma Research, 2022
Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia.
Katagiri S et al.
International Journal of Molecular Sciences, 2022
SmMIP-tools: a computational toolset for processing and analysis of single-molecule molecular inversion probes-derived data.
Medeiros JJF et al.
Bioinformatics (oxford, England), 2022
Tuberous sclerosis complex: a complex case.
Powell RM et al.
Cold Spring Harbor Molecular Case Studies, 2022
Mutational spectrum and precision oncology for biliary tract carcinoma.
Lin J et al.
Theranostics, 2021
KIT and Melanoma: Biological Insights and Clinical Implications.
Pham DDM et al.
Yonsei Medical Journal, 2020
BRAF, KIT, and NRAS Mutations of Acral Melanoma in White Patients.
Dika E et al.
American Journal of Clinical Pathology, 2020
Resistance to TRK inhibition mediated by convergent MAPK pathway activation.
Cocco E et al.
Nature Medicine, 2019
Simultaneous identification of clinically relevant single nucleotide variants, copy number alterations and gene fusions in solid tumors by targeted next-generation sequencing.
Oliveira DM et al.
Oncotarget, 2018
Molecular alterations in lesions of anogenital mammary-like glands and their mammary counterparts including hidradenoma papilliferum, intraductal papilloma, fibroadenoma and phyllodes tumor.
Konstantinova AM et al.
Annals of Diagnostic Pathology, 2017
KIT mutations in primary mediastinal B-cell lymphoma.
Nagel PD et al.
Blood Cancer Journal, 2014
Hotspot mutations in KIT receptor differentially modulate its allosterically coupled conformational dynamics: impact on activation and drug sensitivity.
Chauvot de Beauchêne I et al.
Plos Computational Biology, 2014
Characterization of bone marrow mast cells in acute myeloid leukemia with t(8;21) (q22;q22); RUNX1-RUNX1T1.
Pullarkat ST et al.
Leukemia Research, 2013
KIT, NRAS, and BRAF mutations in nail apparatus melanoma.
Dika E et al.
Pigment Cell & Melanoma Research, 2013
Large-scale analysis of KIT aberrations in Chinese patients with melanoma.
Kong Y et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
The energy landscape analysis of cancer mutations in protein kinases.
Dixit A et al.
Plos One, 2011
Sequence and structure signatures of cancer mutation hotspots in protein kinases.
Dixit A et al.
Plos One, 2009
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
Tang Z et al.
Oncogene, 2009
Recent advances in the understanding of mastocytosis: the role of KIT mutations.
Orfao A et al.
British Journal of Haematology, 2007
Sensitive detection of KIT D816V in patients with mastocytosis.
Tan A et al.
Clinical Chemistry, 2006
Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase.
Foster R et al.
Journal of Molecular Graphics & Modelling, 2004
STAT3 activation is required for Asp(816) mutant c-Kit induced tumorigenicity.
Ning ZQ et al.
Oncogene, 2001